Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

SUMMARY: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Osteoporos Int
Auteurs principaux: Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Format: Artigo
Langue:Inglês
Publié: Springer London 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://ncbi.nlm.nih.gov/pubmed/32935170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-020-05555-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires